International Journal of
ADVANCED RESEARCH & INNOVATIONS

Volume 14, Issue-12
December, 2024, P09
ISSN: 2319-9253

AUTONOMOUS ONCOLOGY SYSTEMS: FOUNDATION MODELS FOR REAL-TIME CLINICAL INTELLIGENCE AND PERSONALIZED CANCER CARE

[#1] **Dr. Akshay Jain**, Assistant Professor, Department of Oncology,
MGM Medical College, Navi Mumbai, India
Akshayjain431@gmail.com

Abstract: Artificial intelligence (AI) is rapidly transforming oncology from a reactive clinical discipline into an autonomous, continuously learning healthcare ecosystem capable of supporting real-time clinical intelligence and personalized cancer care. Conventional clinical decision-making often relies on episodic assessments, fragmented biomedical information, and static predictive models that inadequately reflect the dynamic biological evolution of cancer. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, and generative artificial intelligence have enabled the development of autonomous oncology systems capable of integrating radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, liquid biopsy, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes into unified patient-specific computational frameworks. These intelligent systems continuously learn from evolving biomedical evidence while supporting cancer diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and intelligent clinical decision support. Emerging technologies including multimodal large language models, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen autonomous oncology by enabling collaborative, privacy-preserving, and continuously adaptive computational medicine. Despite remarkable technological advances, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interpretability, interoperability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of autonomous oncology systems, emphasizing foundation AI models for real-time clinical intelligence and personalized cancer care as a transformative paradigm in precision oncology.[1]
Keywords: *Autonomous oncology, Foundation models, Artificial intelligence, Precision oncology, Clinical intelligence, Digital twins, Multimodal learning, Computational oncology, Personalized medicine, Clinical decision support.*

1. Introduction

Cancer is a biologically dynamic disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, tissue remodeling, angiogenesis, and complex interactions among malignant cells, stromal components, immune populations, and host physiology. These interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon computational systems capable of continuously integrating diverse biomedical information.[2]

Modern oncology routinely generates enormous quantities of heterogeneous biomedical data through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, spatial biology, laboratory investigations, liquid biopsy, wearable physiological monitoring, electronic health records, physician documentation, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently overlooks the systems-level mechanisms governing disease progression, therapeutic response, and long-term clinical outcomes.[3]

Artificial intelligence has emerged as a transformative computational technology capable of integrating these heterogeneous biomedical datasets into unified patient-centered representations. Foundation AI models provide generalized multimodal reasoning, while autonomous computational systems continuously adapt to evolving biomedical evidence and patient-specific disease trajectories without requiring repeated manual redevelopment.[4]

The convergence of foundation AI models, autonomous reasoning, digital twins, and precision medicine therefore represents a major paradigm shift toward real-time clinical intelligence capable of transforming personalized cancer care throughout the entire disease continuum.[5]

2. Evolution of Autonomous Oncology Systems

Early computational oncology relied primarily on statistical models and rule-based clinical decision-support systems developed for isolated diagnostic or prognostic tasks. Although these systems improved selected aspects of clinical decision-making, they remained constrained by task-specific architectures, limited adaptability, and fragmented biomedical information.[6]

Deep learning substantially expanded computational capabilities through automated representation learning from radiological imaging, digital pathology, genomic sequencing, and electronic health records. Transformer architectures subsequently revolutionized biomedical artificial intelligence by enabling generalized multimodal representation learning across heterogeneous biomedical datasets.

Foundation AI models have now transformed computational oncology by acquiring transferable biomedical knowledge through large-scale self-supervised learning before adaptation to specialized oncology applications. More recently, reinforcement learning, multimodal large language models, digital twins, federated learning, and agentic AI have established autonomous computational ecosystems capable of continuously learning throughout clinical deployment.

These advances collectively define the emergence of autonomous oncology systems capable of supporting real-time precision medicine.[7]

3. Principles of Autonomous Oncology Systems

Autonomous oncology systems differ fundamentally from conventional artificial intelligence because they function as continuously adaptive computational ecosystems rather than static predictive algorithms. Foundation AI models integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories into unified patient-specific computational representations.[8]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align heterogeneous biomedical modalities within shared computational embedding spaces. Graph neural networks model relationships among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, and clinical outcomes.

Reinforcement learning, continual learning, and agentic AI further enable autonomous reasoning, allowing computational systems to refine clinical recommendations continuously as new biomedical information becomes available while maintaining previously acquired knowledge.[9]

4. Computational Architecture

Modern autonomous oncology platforms consist of interconnected computational layers responsible for multimodal biomedical data acquisition, preprocessing, representation learning, autonomous reasoning, adaptive learning, predictive analytics, digital twin simulation, and intelligent clinical decision support.[10]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological status, and longitudinal clinical trajectories. Autonomous reasoning modules continuously refine predictive representations while supporting diagnosis, therapeutic optimization, disease monitoring, digital twin simulation, and adaptive clinical intelligence.[11]

5. Foundation Models as Autonomous Clinical Intelligence

Foundation AI models constitute the computational intelligence underlying autonomous oncology because they acquire generalized biomedical knowledge from massive multimodal datasets before specialization for individual clinical applications. Unlike conventional task-specific algorithms, foundation models develop transferable computational representations applicable across diagnosis, prognosis, biomarker discovery, therapeutic prediction, computational pathology, radiomics, immunotherapy, disease monitoring, and intelligent clinical decision support.[12]

Transformer architectures enable multimodal attention across imaging, pathology, molecular biology, laboratory investigations, wearable monitoring, and clinical documentation, while graph neural networks characterize interactions among signaling pathways, immune responses, imaging phenotypes, therapeutic targets, physiological variables, and longitudinal clinical outcomes.

These generalized computational capabilities establish foundation AI models as continuously evolving biomedical reasoning engines supporting autonomous precision oncology.[13]

6. Multimodal Biomedical Intelligence

Comprehensive autonomous oncology depends upon seamless integration of complementary biomedical modalities into unified patient-specific computational representations. Radiological imaging provides anatomical and functional characterization of tumors, while digital pathology contributes microscopic tissue architecture, immune infiltration, stromal remodeling, angiogenesis, fibrosis, necrosis, and cellular morphology. Multi-omics technologies—including genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, and spatial biology—provide detailed molecular characterization of evolving tumor biology.[14]

Wearable biosensors continuously monitor physiological parameters including heart rate, physical activity, sleep quality, treatment-related symptoms, medication adherence, and quality-of-life indicators. Laboratory biomarkers, physician documentation, environmental exposures, and electronic health records contribute longitudinal clinical context extending beyond conventional hospital-based assessments.

Artificial intelligence harmonizes these diverse modalities using multimodal transformers, graph neural networks, biological knowledge graphs, and cross-modal attention mechanisms capable of generating adaptive computational embeddings representing continuously evolving patient biology.[15]

7. Real-Time Clinical Intelligence

One of the defining characteristics of autonomous oncology systems is real-time clinical intelligence capable of continuously integrating evolving biomedical information into adaptive computational reasoning. Foundation AI models analyze serial radiological imaging, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical trajectories while

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1209

continuously updating patient-specific disease representations.[16]
Unlike conventional clinical decision-support systems that rely upon periodic reassessment, autonomous systems continuously monitor changes in tumor biology, therapeutic response, physiological status, treatment-related toxicity, and recurrence risk while generating updated evidence-based recommendations throughout the patient's clinical journey.
These adaptive capabilities establish real-time clinical intelligence as a cornerstone of next-generation personalized oncology.[17]

8. Autonomous Biomarker Discovery

Foundation AI models substantially enhance biomarker discovery by continuously integrating radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, and longitudinal clinical outcomes into comprehensive multimodal computational frameworks. Artificial intelligence identifies emerging biological signatures associated with molecular subtypes, therapeutic sensitivity, immune activation, treatment resistance, toxicity, recurrence, metastatic progression, and survival while continuously refining computational biomarker performance as new clinical evidence becomes available.[18]
These adaptive computational biomarkers improve individualized therapeutic stratification, accelerate translational oncology research, and strengthen evidence-based precision medicine by evolving alongside advances in biomedical science and clinical practice.[19]

9. Personalized Therapeutic Decision-Making

One of the most transformative applications of autonomous oncology systems is individualized therapeutic decision-making through continuous integration of imaging phenotypes, histopathological characteristics, molecular biology, laboratory biomarkers, wearable physiological monitoring, medication history, and longitudinal clinical trajectories. Foundation AI models continuously refine predictions regarding responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while adapting therapeutic recommendations according to evolving patient biology and real-world clinical outcomes.[20]

10. Digital Twins and Autonomous Virtual Patients

Digital twin technology represents one of the most transformative components of autonomous oncology systems by creating continuously evolving virtual representations of individual cancer patients synchronized with their biological counterparts. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]
Unlike conventional predictive models, autonomous digital twins continuously update their computational representations as new biomedical information becomes available. These intelligent virtual patients allow clinicians to evaluate multiple therapeutic strategies before implementation, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology.
By combining multimodal biomedical intelligence with predictive simulation, autonomous digital twins transform computational oncology from retrospective analysis toward proactive precision medicine supported by continuously adaptive virtual patient ecosystems.

11. Intelligent Clinical Decision Support

Autonomous oncology systems provide the computational infrastructure for next-generation clinical decision-support platforms capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1209

physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, foundation AI models synthesize these diverse information sources into unified computational representations supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, multimodal biomarker analyses, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, and survival predictions while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce fragmentation of biomedical information, and promote evidence-based personalized cancer management throughout the cancer care continuum.

12. Continuous Learning and Adaptive Intelligence

A defining characteristic of autonomous oncology systems is their ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes therapeutic recommendations through iterative evaluation of treatment outcomes. Consequently, autonomous oncology systems remain synchronized with evolving tumor biology, emerging scientific discoveries, changing clinical guidelines, and diverse patient trajectories.

This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting real-time personalized precision medicine.

13. Federated Autonomous Oncology Networks

Development of highly generalizable autonomous oncology systems requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, molecular technologies, treatment protocols, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local models using radiological imaging, digital pathology, genomic sequencing, laboratory investigations, wearable monitoring, liquid biopsy, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, and generalizability across diverse healthcare environments.

Federated autonomous oncology ecosystems therefore establish an international computational oncology network capable of accelerating scientific discovery, improving equitable access to precision medicine, and supporting global cancer research while maintaining responsible data stewardship.

14. Explainability, Validation, and Ethical Governance

Successful implementation of autonomous oncology systems requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations identifying the

Volume 14, Issue-12
December, 2024, P09
ISSN: 2319-9253

imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon protection of patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, and continuous post-deployment surveillance to ensure trustworthy integration of autonomous computational systems into routine oncology practice.

15. Future Perspectives

Future autonomous oncology systems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, cloud-native healthcare infrastructure, and autonomous clinical reasoning systems into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, imaging, pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence.

Such intelligent ecosystems are expected to transform oncology from fragmented and reactive disease management toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

Autonomous oncology systems represent one of the most significant paradigm shifts in computational oncology by integrating molecular biology, imaging, pathology, digital twins, multimodal biomedical intelligence, and longitudinal clinical reasoning into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional artificial intelligence systems developed for isolated predictive tasks, these intelligent frameworks simultaneously analyze molecular biology, tissue architecture, radiological imaging, laboratory biomarkers, physiological monitoring, environmental influences, and longitudinal clinical trajectories to generate holistic representations of evolving cancer biology.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of autonomous artificial intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, autonomous oncology systems are expected to become the central computational infrastructure supporting intelligent precision oncology worldwide.

17. Conclusion

Autonomous oncology systems are transforming personalized cancer care by integrating foundation AI models, radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1209

optimization, adaptive disease monitoring, and individualized clinical decision-making throughout the disease continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen autonomous oncology ecosystems, enabling increasingly accurate molecular characterization, predictive clinical intelligence, adaptive therapeutics, continuous disease surveillance, and continuously personalized precision oncology.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of autonomous oncology systems. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.
3. Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.
4. Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.
5. Kather, J.N. et al. (2022) ‘Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations’, Nature Cancer, 3(7), pp. 789-799.
6. Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.
7. Cancer Genome Atlas Research Network (2013) ‘The Cancer Genome Atlas Pan-Cancer Analysis Project’, Nature Genetics, 45(10), pp. 1113-1120.
8. Huang, S.C. et al. (2021) ‘Self-supervised Learning for Medical Image Classification: A Systematic Review’, IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
9. Moor, M. et al. (2023) ‘Foundation Models for Generalist Medical Artificial Intelligence’, Nature, 616(7956), pp. 259-265.
10. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
11. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
12. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
13. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
14. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
15. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
16. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

17. 17. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304, DOI: https://doi.org/10.46121/pspc.51.2.7
18. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
19. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323, DOI: https://doi.org/10.46121/pspc.51.4.5
20. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303, DOI: https://doi.org/10.46121/pspc.52.1.5
21. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324, DOI: https://doi.org/10.46121/pspc.52.2.14
22. 22. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
23. 23. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345, DOI: https://doi.org/10.46121/pspc.52.2.18
24. 24. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388, DOI: https://doi.org/10.46121/pspc.51.4.7
25. 25. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
26. 26. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343, DOI: https://doi.org/10.46121/pspc.52.4.16
27. 27. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
28. 28. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System

Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312, DOI: https://doi.org/10.46121/pspc.52.4.13.

29. 29. Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.

30. 30. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8